GB LABS

INVESTOR RELATIONS · 2026

PainFree 8800

Investor Presentation

A pain-treatment medical device business
with licenses and quality systems in place

Class III combination device · Manufacturing · Export license · GMP · ISO 13485 · Patent



October 2026 · Draft for review
Investment terms to be finalized after negotiation

01. Disclaimer and Contents

Please read first

DISCLAIMER

· This document is not an investment solicitation; investors are responsible for their own decisions.
· Licenses, certificates and IP are based on copies, pending verification against originals.
· Inventory, mold and market figures are internal estimates or third-party forecasts.
· Investment amount, structure and valuation are left blank until agreed.
· 'Illustrative image' marks AI-generated images.

CONTENTS

01 Investment Highlights
02 Business Overview
03 Asset Summary
04 Market Opportunity
05 Revenue Model and Unit Economics
06 Structure and Clean-up Tasks
07 Deal Structure and Conditions
08 Use of Funds and Milestones
09 Risks and Responses



Actual product photo

02. Investment Highlights

Why invest



01

Regulatory barrier

Class III combination license, manufacturing business license and export license already held



02

Six-in-one

Six licensed items in one device; most competitors hold a single item



03

Proven concept

Source technology: CE, FDA, Korean New Health Technology, fee code MZ012



04

Ready to produce

Molds, finished units and parts on hand (internal estimate, before due diligence)



05

Expert leadership

Led by a digital health company headed by a pain medicine specialist

Some photos are illustrative. Supporting detail for each figure follows on later pages.

03. Business Overview

Product and business

Product	PainFree8800 (PainFree S8800) · pain-treatment combination device
Modalities	Transcutaneous electrical (Scrambler type) · laser · ultrasound · PEMF · low-frequency · thermal
Forms	Tabletop · stand (thermal belt and footplate)
License	MFDS Class III · No. 20-20 · valid to 2030.08.31
Quality	Medical device GMP · ISO 13485:2016
Sponsor	GB LABS & GBI (CEO Lim Chun-hak)
Customers	Pain and rehab clinics · long-term care hospitals · public procurement · export

With licenses, quality systems, IP and production assets already in place, funds go to **incorporation and sales expansion**.



04. Asset Summary

What we hold

Asset	Detail	Current holder	Status
Mfg. business license	**No. 6094 (2018.05.23)**	**GM (sole proprietor)**	**Transfer to corporation**
Domestic product license	**No. 20-20 · 6 items · Class III**	**GM (sole proprietor)**	**Transfer to corporation**
Export license	No. 19-427 · 5 items	Contract manufacturer listed (Solco Hitech)	Holder to be aligned
Quality certificates	GMP · ISO 13485	GM	2026 renewal evidence pending
Intellectual property	**1 patent · 3 designs · 1 utility model**	**GBI (by assignment)**	**Register change to confirm**
Production assets	Molds · ~400 finished units · parts	GM	Internal estimate · due diligence needed










05. Market Opportunity

Demand outlook

GLOBAL PAIN MANAGEMENT DEVICES (USD 100M, FORECAST)



USD 5.8B by 2029 · 9.1% CAGR (MarketsandMarkets). 2024 and 2026 are back-calculated from the growth rate for reference.

20%

Share of Koreans aged 65+ (Dec 2024)

~10%

Adult chronic pain prevalence (estimate)

As Korea becomes a super-aged society, demand grows for **long-term, drug-free pain management**.




06. Revenue Model and Unit Economics

How we earn

Stream	Description
Device sales	Direct sales to clinics and hospitals, plus distributors
Rental · lease	Monthly plans that lower upfront cost
Consumables	Recurring sales of electrode pads and more
Public procurement	Public Procurement Service channel
Export	Based on export license, after local regulatory review
Training · service	User training and maintenance

Clinic example (assumption): KRW 150,000 × 3 patients/day × 20 days = **KRW 9 million/month**

CLINIC PAYBACK EXAMPLE (MONTHS)



A simple example using competitor price ranges; excludes labor and consumables; not PainFree8800's price.

07. Structure and Clean-up Tasks

Corporate structure

TODAY

GM (sole proprietor)

Mfg. and product licenses · GMP · ISO
Molds · inventory · parts

›

CLEAN-UP

New corporation

Assets transferred by in-kind contribution
License holder transfer
IP re-assignment or exclusive license

›

INVESTMENT TARGET

Restructured corporation

Valuation by external appraisal
Milestone-linked funding

Intellectual property


Assigned from inventor to GBI. After confirming the register change, decide how it vests in the new corporation.

Export license

Contract manufacturer listed → plan to align the holder.

Entity naming

Separate and unify GM, GM R&D, GBI and GB LABS by legal name and brand.



08. Deal Structure and Conditions Precedent

Draft terms

INVESTMENT TERMS (TO BE AGREED)

Instrument	[ ]
Target	[Restructured corporation]
Amount	[ ]
Valuation	[Based on external accounting firm appraisal]
Disbursement	Staged, linked to milestones

Bracketed items will be completed per party negotiation and appraisal results.

CONDITIONS PRECEDENT (CP)

① Vesting in the corporation

Licenses, certificates and IP vested in the new corporation

② Due diligence

Inventory and mold inspection and appraisal reflected

③ Renewal evidence

2026 GMP and ISO 13485 renewal evidence secured







09. Use of Funds and Milestones

Plan

USE OF FUNDS (SHARES TBD)

Legal and organization	[ ]%
R&D center · clinical (IIT)	[ ]%
Sales · marketing · rental stock	[ ]%
Overseas certification · export	[ ]%
Working capital	[ ]%

MILESTONES

M+3
Incorporation · IP transfer · license holder change

M+6
R&D center · IIT approval · rental launch

M+12
More client sites · first procurement delivery

M+24
Revenue track record · one overseas certification underway

M+36
First export contract · follow-on round or partnership



10. Risks and Responses

Key risks

Risk	Description	Response
Regulatory · holder	Licenses held by a sole proprietor · export license manufacturer mismatch	Vesting in corporation as a CP; invest after completion
Renewal	GMP and ISO on 3-year cycles; product license renewal 2030.08	Renewal schedule management · evidence
Claims	Over-claiming beyond licensed scope	Wording register based on licensed intended use
Clinical	Limited product-specific evidence	Investigator-initiated trials (IIT) · publication
Market · price	Slow adoption · non-covered fee transparency	Rental · pilot programs · procurement channel
Inventory · key person	Realizability of inventory value · reliance on the CEO	Due diligence and appraisal · organization and documentation







IR CONTACT

Investor Inquiries

GB LABS & GBI Co., Ltd.

145 Anam-ro, Seongbuk-gu, Seoul, Korea

gblabs.co.kr

GB LABS



This is a draft for review, not an investment solicitation. Terms are finalized only by agreement between the parties and required approvals.